Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Liabilities: 2021-2024

Historic Total Liabilities for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $94.4 million.

  • ARS Pharmaceuticals' Total Liabilities rose 1254.44% to $225.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.1 million, marking a year-over-year increase of 1254.44%. This contributed to the annual value of $94.4 million for FY2024, which is 3786.12% up from last year.
  • According to the latest figures from FY2024, ARS Pharmaceuticals' Total Liabilities is $94.4 million, which was up 3,786.12% from $2.4 million recorded in FY2023.
  • ARS Pharmaceuticals' Total Liabilities' 5-year high stood at $94.4 million during FY2024, with a 5-year trough of $2.4 million in FY2023.
  • Moreover, its 3-year median value for Total Liabilities was $8.5 million (2022), whereas its average is $35.1 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first plummeted by 71.60% in 2023, then skyrocketed by 3,786.12% in 2024.
  • ARS Pharmaceuticals' Total Liabilities (Yearly) stood at $16.7 million in 2021, then crashed by 48.73% to $8.5 million in 2022, then slumped by 71.60% to $2.4 million in 2023, then spiked by 3,786.12% to $94.4 million in 2024.